menu
    • menu
    [{"orgOrder":0,"company":"Vaxine","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Jack Jumper Venom","moa":"Immune system","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"7","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Central Adelaide Local Health Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Central Adelaide Local Health Network","highestDevelopmentStatusID":"6","companyTruncated":"Vaxine \/ Central Adelaide Local Health Network"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute Ltd"},{"orgOrder":0,"company":"Vaxine","sponsor":"Medytox","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Covax-19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Medytox","highestDevelopmentStatusID":"4","companyTruncated":"Vaxine \/ Medytox"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute","highestDevelopmentStatusID":"7","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute"},{"orgOrder":0,"company":"Vaxine","sponsor":"Flinders Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Flinders Medical Centre","highestDevelopmentStatusID":"6","companyTruncated":"Vaxine \/ Flinders Medical Centre"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Adjuvanted Recombinant Spike Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CinnaGen COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute | CinnaGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CinnaGen COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute | CinnaGen","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute | CinnaGen"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Virus-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Radvax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute","highestDevelopmentStatusID":"6","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute"},{"orgOrder":0,"company":"Vaxine","sponsor":"Flinders University | Australian Respiratory and Sleep Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Recombinant Influenza Hemagglutinin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Flinders University | Australian Respiratory and Sleep Medicine Institute","highestDevelopmentStatusID":"6","companyTruncated":"Vaxine \/ Flinders University | Australian Respiratory and Sleep Medicine Institute"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Influenza Hemagglutinin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute","highestDevelopmentStatusID":"6","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute"},{"orgOrder":0,"company":"Vaxine","sponsor":"Prestige BioPharma Pte Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Covax-19","moa":"SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"15","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Advax-SM","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 recombinant spike protein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Vaxine"}]

    Find Clinical Drug Pipeline Developments & Deals by Vaxine

    Menu

    Vaxine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Australian Respiratory and Sleep Medicine Institute Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Covid-19 and Influenza Oral Vaccine Study

                            Details : COVID-19 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 09, 2024

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Australian Respiratory and Sleep Medicine Institute Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radvax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Australian Respiratory and Sleep Medicine Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Tumour Vaccine Trial

                            Details : Radvax is a Virus-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Virus-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 10, 2023

                            Lead Product(s) : Radvax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Australian Respiratory and Sleep Medicine Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CinnaGen COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Booster Study of SpikoGen COVID-19 Vaccine

                            Details : CinnaGen COVID-19 vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 16, 2022

                            Lead Product(s) : CinnaGen COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine,Covax-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Prestige BioPharma Pte Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influe...

                            Details : Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/inf...

                            Product Name : SpikoGen

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 30, 2022

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine,Covax-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Prestige BioPharma Pte Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adjuvanted Recombinant Spike Protein COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Australian Respiratory and Sleep Medicine Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

                            Details : Adjuvanted Recombinant Spike Protein COVID-19 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 15, 2022

                            Lead Product(s) : Adjuvanted Recombinant Spike Protein COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Australian Respiratory and Sleep Medicine Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 recombinant spike protein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years...

                            Details : SARS-CoV-2 recombinant spike protein is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 09, 2022

                            Lead Product(s) : SARS-CoV-2 recombinant spike protein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

                            Details : SpikoGen (Recombinant protein-based COVID-19 vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : SpikoGen

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CinnaGen COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Australian Respiratory and Sleep Medicine Institute | CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

                            Details : CinnaGen COVID-19 vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 08, 2021

                            Lead Product(s) : CinnaGen COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Australian Respiratory and Sleep Medicine Institute | CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine,Covax-19,Advax-SM

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months

                            Details : SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.

                            Product Name : SpikoGen

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 16, 2021

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine,Covax-19,Advax-SM

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Vaxine

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

                            Details : SpikoGen (Recombinant protein-based COVID-19 vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : SpikoGen

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 13, 2021

                            Lead Product(s) : Recombinant protein-based COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : CinnaGen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth